On January 5, 2010, Silence Therapeutics completed its merger with Intradigm. A new website for the merged company is under development. In the meantime, please visit www.silence-therapeutics.com.
THERAPEUTIC PLATFORM
Sequence Library
The ability to effectively select appropriate disease targets plays a critical role in the development and optimization of RNAi therapeutics.
KEY SEQUENCE FEATURES |
|
 |
To maximize target selection success, Intradigm weighs a number of critical considerations including the role the target plays in disease modification, the cell type in which the target is expressed, and the potential freedom to operate in developing a therapeutic against the target. Through diligent scientific research based on bioinformatics algorithms and unique know-how, Intradigm has compiled a library of proprietary siRNA sequences against more than 50 high-value disease targets.